Octreotide Acetate

Indicated for the treatment of patients two years of age and older with gastrointestinal infections caused by Ancylostoma duodenale (hookworm), Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Necator americanus (hookworm), and Trichuris trichiura (whipworm).

Indicated for the treatment of symptomatic orthostatic hypotension (OH).

Indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test

Indicated for treatment of Idiopathic Pulmonary Fibrosis,  Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype, Systemic Sclerosis-Associated Interstitial Lung Disease

Indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

For the temporary relief of symptoms of food cravings, including: constant appetite, increased or insatiable hunger. The peripheral actions of oxytocin mainly reflect secretion from the pituitary gland.
Purity not les sthan 99% Complete impurity characterization available

Indium In-111 pentetreotide is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.

Indicated in adults for the treatment of: chronic idiopathic constipation (CIC).  irritable bowel syndrome with constipation (IBS-C)

Indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.

Iindicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

Indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Brochure of the company for referring to Company's work profile, strengths, capabilities and facility information.